We believe that the current overall low potency of synthetic TRAIL homologs represents the most critical hurdle to the success of TRAIL-based therapy; in that context, we anticipate that our results could, given time, form the basis of novel therapeutic strategies involving the targeting of nuclear-cytoplasmic shuttling mechanisms in order to sensitize tumor cells to the effect of TRAIL. This evidence concerns the gene TNFSF10 and neoplasm.